Nogapendekin alfa inbakicept
Anktiva is a bladder-instilled immune booster given with BCG for early bladder cancer that has stopped responding to BCG, offering many patients a way to keep their bladder rather than have it removed.
Overview
Nogapendekin alfa inbakicept (Anktiva, formerly N-803) is an engineered version of interleukin-15, a signal that drives natural killer and killer T cells. It is instilled into the bladder together with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that has become unresponsive to BCG, a setting where the standard alternative is removal of the bladder. In the single-arm QUILT-3.032 trial most patients with carcinoma in situ had a complete response and many responses lasted more than a year. The FDA approved it in April 2024. In England NICE published a terminated evaluation in June 2026, so it is not routinely funded there.
A long-acting IL-15 receptor agonist that expands and activates natural killer cells and CD8 T cells in the bladder wall, so that BCG can trigger an immune response in tumours that no longer respond to BCG alone.
1.Nogapendekin alfa inbakicept binds its target.
- Appraised for
- With BCG for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ
- Notes
- Terminated evaluation published 4 June 2026: NICE stopped the appraisal, so the medicine is not routinely funded in England. FDA-approved (Anktiva) since April 2024.
Sources: NICE TA1163. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2024 | With BCG for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumours |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Nogapendekin alfa inbakicept" OR ABSTRACT:"Nogapendekin alfa inbakicept" OR TITLE:"Anktiva" OR ABSTRACT:"Anktiva" OR TITLE:"N-803" OR ABSTRACT:"N-803" OR TITLE:"ALT-803" OR ABSTRACT:"ALT-803" OR TITLE:"NAI" OR ABSTRACT:"NAI") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Nogapendekin alfa inbakicept, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentMifamurtide
Shares Cytokines & engineered cytokines and the tag gap-fill.
- TreatmentRopeginterferon alfa-2b
Shares Cytokines & engineered cytokines and the tag gap-fill.
- TargetEpCAM
Shares Bladder & urothelial cancer and the tag gap-fill.
- TargetPRMT5 (MTAP-deleted cancers)
Shares Bladder & urothelial cancer and the tag gap-fill.
- TreatmentMitomycin C
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer and the tag gap-fill.
- TreatmentNogapendekin alfa inbakicept
Shares ImmunityBio, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Cytokines & engineered cytokines, Bladder & urothelial cancer.
- TreatmentAldesleukin (high-dose IL-2)
Shares Cytokines & engineered cytokines and the tag gap-fill.
- TreatmentInterferon alfa-2a/2b
Shares Cytokines & engineered cytokines and the tag gap-fill.